MRUS241220P20000
- 0.00
- 0.000.00%
Merus Newsroom
Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Pyxis Stock Craters 46% Amid Phase 1 Data, William Blair Downgrade
Goldman Sachs Initiates Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Merus Initiated With a Buy at Goldman Sachs
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Truist Financial Initiates Merus(MRUS.US) With Buy Rating
Truist Financial Remains a Buy on Merus (MRUS)
Express News | Needham Reiterates Buy on Merus, Maintains $85 Price Target
Merus Analyst Ratings
Merus's Stock Poised for Growth Amidst Promising Data and Market Positioning
EQT Life Sciences Leads €54 Million Series A Financing of ATB Therapeutics
Merus Management to Meet With Truist
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event
Express News | Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology
Merus to Present at Upcoming Investor Conferences
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Fresenius Medical Care (FMS) and Treace Medical Concepts (TMCI)
Express News | U.s-Listed Shares of Merus NV Down 4.5% After FDA Extends Review of Co's Gene-Targeting Cancer Therapy
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100